Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marco Poggiu"'
Autor:
Sara Bringhen, Mattia D’Agostino, Laura Paris, Stelvio Ballanti, Norbert Pescosta, Stefano Spada, Sara Pezzatti, Mariella Grasso, Delia Rota-Scalabrini, Luca De Rosa, Vincenzo Pavone, Giulia Gazzera, Sara Aquino, Marco Poggiu, Armando Santoro, Massimo Gentile, Luca Baldini, Maria Teresa Petrucci, Patrizia Tosi, Roberto Marasca, Claudia Cellini, Antonio Palumbo, Patrizia Falco, Roman Hájek, Mario Boccadoro, Alessandra Larocca
Publikováno v:
Haematologica, Vol 105, Iss 7 (2020)
n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma. After induction, patients were randomly ass
Externí odkaz:
https://doaj.org/article/9b964beaa1304beda086763a5297de0d
Autor:
Semra Aydin, Roberto Passera, Matilde Scaldaferri, Chiara Maria Dellacasa, Marco Poggiu, Francesco Cattel, Francesco Zallio, Lucia Brunello, Luisa Giaccone, Irene Dogliotti, Alessandro Busca
Publikováno v:
International Journal of Hematology. 116:883-891
In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c759e650e7433106e5affc881ba7b33
https://doi.org/10.1007/s12185-022-03427-4
https://doi.org/10.1007/s12185-022-03427-4
Autor:
Norbert Pescosta, Delia Rota Scalabrini, Katia Mancuso, Giovanni De Sabbata, Gloria Margiotta Casaluci, Michele Cea, Mario Boccadoro, Monica Galli, Anna Baraldi, Mariella Grasso, Angelo Belotti, Nicola Cascavilla, Maria Teresa Petrucci, Marco Poggiu, Sara Aquino, Sara Bringhen, Roberto Mina, Vanessa Innao, Francesca Patriarca, Massimo Offidani, Claudia Cellini, Renato Zambello, Anna Marina Liberati, Alessandra Larocca, Andrea Capra, Paolo Corradini, Giovannino Ciccone, Stelvio Ballanti
INTRODUCTION. Bortezomib- and/or lenalidomide-based combinations are standard initial approaches in transplant (ASCT) ineligible NDMM. Different studies confirmed the advantages of continuous treatment. Despite the benefits of bortezomib maintenance,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb2b08ad219034f2c4a7a73a4e9ec898
http://hdl.handle.net/11570/3171800
http://hdl.handle.net/11570/3171800
Autor:
Mattia D'Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, Elisa Genuardi, Francesco Maura, Stefania Oliva, Daniel Auclair, Jennifer Yesil, Andrea Capra, Paola Colucci, Marco Poggiu, Jonathan Keats, Alessandra Larocca, Manuela Gambella, Niccolo Bolli, Mario Boccadoro, Francesca Gay
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e13-e14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93ccf45fe3f686dd65482a75851e2d6f
https://doi.org/10.1016/j.clml.2019.09.019
https://doi.org/10.1016/j.clml.2019.09.019